Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
APVO Aptevo Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: APVO
Price (delayed)
$0.312
Market cap
$2.53M
P/E Ratio
0.02
Dividend/share
N/A
EPS
$14.05
Enterprise value
$4.81M
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603,
Highlights
APVO's EPS has surged by 116% since the previous quarter and by 100% year-on-year
The company's debt fell by 15% YoY and by 4.5% QoQ
Aptevo Therapeutics's equity has shrunk by 131% QoQ and by 124% YoY
The quick ratio has plunged by 75% YoY and by 71% from the previous quarter
Key stats
What are the main financial stats of APVO
Market
Valuations
Earnings
Shares outstanding
8.11M
Market cap
$2.53M
Enterprise value
$4.81M
Price to earnings (P/E)
0.02
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$24.1M
Net income
-$23.7M
EBIT
-$23.7M
EBITDA
-$23.4M
Free cash flow
-$23.71M
Per share
Balance sheet
Liquidity
EPS
$14.05
EPS diluted
$14.05
Free cash flow per share
-$16.26
Book value per share
-$1.01
Revenue per share
$0
TBVPS
$5.72
Total assets
$8.34M
Total liabilities
$9.82M
Debt
$4.42M
Equity
-$1.47M
Working capital
-$1.79M
Debt to equity
-3
Current ratio
0.67
Quick ratio
0.4
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-175.6%
Return on equity
-779.4%
Return on invested capital
-406.4%
Return on capital employed
-803.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APVO stock price
How has the Aptevo Therapeutics stock price performed over time
Intraday
-17.89%
1 week
-5.45%
1 month
-55%
1 year
-98.88%
YTD
-92.76%
QTD
-73.1%
Financial performance
How have Aptevo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.1M
Net income
-$23.7M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 14% YoY and by 2% QoQ
APVO's net income is up by 12% YoY
Price vs fundamentals
How does APVO's price correlate with its fundamentals
Growth
What is Aptevo Therapeutics's growth rate over time
Valuation
What is Aptevo Therapeutics stock price valuation
P/E
0.02
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APVO's EPS has surged by 116% since the previous quarter and by 100% year-on-year
Aptevo Therapeutics's equity has shrunk by 131% QoQ and by 124% YoY
Efficiency
How efficient is Aptevo Therapeutics business performance
Aptevo Therapeutics's ROA has plunged by 60% YoY and by 15% from the previous quarter
The return on equity has dropped by 59% since the previous quarter
The company's return on invested capital fell by 2.7% QoQ but it rose by 2.6% YoY
Dividends
What is APVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APVO.
Financial health
How did Aptevo Therapeutics financials performed over time
APVO's total assets is 15% lower than its total liabilities
The quick ratio has plunged by 75% YoY and by 71% from the previous quarter
The company's current ratio has shrunk by 65% YoY and by 61% QoQ
Aptevo Therapeutics's equity has shrunk by 131% QoQ and by 124% YoY
The company's debt fell by 15% YoY and by 4.5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.